Skip to main content
Apply for Grants

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

  • ${value}

Filter Results (2139${count})

  • Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022
    Therapeutic Efficacy of IC 100 in Small Models

    Study Rationale: Parkinson’s disease (PD) is characterized by the loss of neurons in the brain. Despite available treatments, no approved therapy can slow disease progression. Data in humans and small...

  • Fall 2021 RFP: Outcome Measures, 2022
    Pet Imaging to Determine Regional and Temporal Trajectories of Reactive Astrocytosis in Parkinson’s Disease

    Study Rationale: Neuroinflammation is a known process accompanying Parkinson’s disease (PD) neuropathology. During this process, specific brain cell populations become chronically activated, including...

  • Fall 2021 RFP: Outcome Measures, 2022
    LRRK2 Kinase Activity and Global Proteomic Biomarkers in the Gut of Patients with Parkinson’s and/or Inflammatory Bowl Disease

    Study Rationale: Accumulative evidence suggests a strong connection between the brain and the gut, with chronic intestinal inflammation being linked to an increased risk of Parkinson’s disease (PD)...

  • Spring 2022 RFP: Expanding Biological Understanding of Parkinson's Disease, 2022
    The Role of Acid Ceramidase in GBA1 in Parkinson’s Disease

    Study Rationale: Mutations in the GBA1 gene are one of the most common risk factor for Parkinson’s disease (PD). GBA1 encodes glucocerebrosidase, an enzyme that breaks down a lipid called...

  • Research Grant, 2022
    Undiagnosed Parkinson’s in the Emergency Department: An Opportunity for Early Intervention

    Study Rationale: Many patients diagnosed with Parkinson’s disease had signs or symptoms of the disease years before an actual diagnosis is made. An astonishingly high percentage of these patients are...

  • Winter 2021 RFA: Alpha-synuclein Seed Amplification Assay Program, 2022
    Digital Detection of Alpha-synuclein Aggregates for the Quantitative Diagnosis of Parkinson’s disease

    Study Rationale: The detection of protein aggregates is currently at the leading edge of diagnostic developments in Parkinson’s disease and other age-related disorders. There is demand for...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.